These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38633140)

  • 1. Long-Term Control With Proton Beam Therapy for Recurrent Prostate Cancer in the Right Perineum Following Intensity-Modulated Radiation Therapy: A Case Report.
    Ishikawa Y; Suzuki M; Seto I; Takagawa Y; Murakami M
    Cureus; 2024 Apr; 16(4):e58386. PubMed ID: 38633140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
    Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
    BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
    Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
    Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
    Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
    Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
    Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
    [No Abstract]   [Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
    Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-Matched Outcomes of Proton Beam and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
    Bao A; Barsky AR; Both S; Christodouleas JP; Deville C; Tochner ZA; Vapiwala N; Maxwell R
    Int J Part Ther; 2023; 10(1):1-12. PubMed ID: 37823012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Shiraishi Y; Xu C; Yang J; Komaki R; Lin SH
    Radiother Oncol; 2017 Oct; 125(1):48-54. PubMed ID: 28917586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
    Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Biagioli MC
    Brachytherapy; 2014; 13(2):123-7. PubMed ID: 24269146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA
    J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.
    Remick JS; Schonewolf C; Gabriel P; Doucette A; Levin WP; Kucharczuk JC; Singhal S; Pechet TTV; Rengan R; Simone CB; Berman AT
    Clin Lung Cancer; 2017 Jul; 18(4):364-371. PubMed ID: 28162946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy.
    Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Yu HJ; Lai MK; Liu SP; Pu YS; Cheng JC
    Oncotarget; 2016 Jul; 7(28):44224-44235. PubMed ID: 27317764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
    Bai M; Gergelis KR; Sir M; Whitaker TJ; Routman DM; Stish BJ; Davis BJ; Pisansky TM; Choo R
    Cancer Med; 2020 Nov; 9(21):7925-7934. PubMed ID: 32931662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy.
    Ojerholm E; Kirk ML; Thompson RF; Zhai H; Metz JM; Both S; Ben-Josef E; Plastaras JP
    Acta Oncol; 2015; 54(8):1209-17. PubMed ID: 25734796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
    Carrasquilla M; Sholklapper T; Pepin AN; Hodgins N; Lei S; Rashid A; Danner M; Zwart A; Bolanos G; Ayoob M; Yung T; Aghdam N; Collins B; Suy S; Kumar D; Hankins R; Kowalczyk K; Dawson N; Collins S
    Front Oncol; 2023; 13():1240939. PubMed ID: 38074646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
    Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of late adverse events in proton beam therapy for prostate cancer.
    Makishima H; Ishikawa H; Tanaka K; Mori Y; Mizumoto M; Ohnishi K; Aihara T; Fukumitsu N; Okumura T; Sakurai H
    Mol Clin Oncol; 2017 Oct; 7(4):547-552. PubMed ID: 29046789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
    Silva NN; Eng C
    J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.